In 2025, it was estimated that there would be over 972 thousand new cancer cases among women in the United States. This statistic illustrates the estimated number of new cancer cases and deaths in the United States for 2025, by gender.

The graph illustrates the number of deaths from cancer in the United States over the period from 1999 to 2023. The x-axis represents the years, labeled with two-digit abbreviations from '99 to '23, while the y-axis displays the annual number of cancer-related deaths. Throughout this 25-year span, the number of deaths ranges from a minimum of 549,829 in 1999 to a maximum of 613,349 in 2023. The data shows a gradual increase in annual deaths over the years. Notably, the number surpassed 550,000 in 2000 with 553,080 deaths, reached 574,738 in 2010, and exceeded 600,000 in 2020 with 602,347 deaths. The figures continued to rise, culminating in the highest recorded number of 613,349 deaths in 2023.

In the period between 2018 and 2022, there were approximately 179 cancer deaths per 100,000 white males in the United States. This statistic shows cancer death rates in the United States for the period 2018-2022, by ethnic group and gender.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Provisional death counts of malignant neoplasms (cancer) by month and year, and other selected demographics, for 2020-2021. Data are based on death certificates for U.S. residents.

The highest number of cancer deaths in the given period was 605,206, reported in 2021. The lowest number of cancer deaths was 549,829 in 1999. This statistic shows the total number of cancer deaths in the United States from 1999 to 2021.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

In the United States, the leading causes of death among women are heart disease and cancer. Heart disease and cancer are similarly the leading causes of death among U.S. men. In 2023, heart disease accounted for **** percent of all deaths among women in the United States, while cancer accounted for **** percent of deaths. COVID-19 was the third leading cause of death among women in 2020 and 2021, and the fourth leading cause in 2022, however, by 2023 it had dropped to ninth place. Cancer among women in the U.S. The most common types of cancer among U.S. women are breast, lung and bronchus, and colon and rectum. In 2025, there were around ******* new breast cancer cases among women, compared to ******* new cases of lung and bronchus cancer. Although breast cancer is the most common form of cancer among women in the United States, lung and bronchus cancer causes the highest number of cancer deaths. In 2025, around ****** women were expected to die from lung and bronchus cancer, compared to ****** from breast cancer. Breast cancer Although breast cancer is the second most deadly form of cancer among women, rates of death have decreased over the past few decades. This decrease is possibly due to early detection, progress in therapy, and increasing awareness of risk factors. In 2023, the death rate due to breast cancer was **** per 100,000 population, compared to a rate of **** per 100,000 in the year 1990. The state with the highest rate of deaths due to breast cancer is Oklahoma, while South Dakota had the lowest rates.

In 2019-2020, around 11.3 percent of those who had served in the U.S. military reported being diagnosed with some form of cancer. This statistic shows the percentage of those who have served/not served in the U.S. military who reported being told by a health professional that they had some form of cancer in 2019-2020.

In the period 2017-2021, around *** men in the United States per 100,000 population developed some type of cancer, compared to *** women per 100,000 population. This statistic shows the incidence rates for cancer in the U.S. for the period from 2017 to 2021, by gender.

Data support a paper of this title:

A Geotemporospatial and Causal Inference Epidemiological Exploration of Substance and Cannabinoid Exposure as Drivers of Rising US Pediatric Cancer Rates

Data represent a compilation of various data inputs from numerous sources including the National Cancer Institute SEER*Stat National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database, 2019 submission (2001-2017), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2020. Available at www.cdc.gov/cancer/public-use program; the National survey of Drug Use and Health conducted by the Substance Abuse and Mental Health Services Administration; and the US Census bureau.

Data also include inverse probability weights for cannabis exposure.

Data also include their geospatial linkage network constructed for all US states which makes Alaska and Hawaii spatially connected to the contiguous USA.

Data also include the R script used to conduct and prepare the analysis.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The 19 cancer sites currently covered by Get Data Out are: ‘Bladder, urethra, renal pelvis and ureter’, ‘Bone’, ‘Brain’, ‘Eye’, ‘Blood cancer (haematological neoplasms)’, ‘Blood cancer (haematological neoplasm) transformations’, ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, ‘Liver and biliary tract’, ‘Lung, mesothelioma, and other thoracic', Oesophagus and stomach’, ‘Ovary’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue’, ‘Testes’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. This release covers a refresh of the 2013-2020 incidence data plus the addition of the diagnosis years 2021 and 2022 for incidence. It also covers a refresh of the 2013-2020 treatment data plus the addition of the diagnosis year 2021 for treatment statistics. It also covers a refresh of the 2013-2018 routes to diagnosis data plus the addition of the diagnosis years 2019 and 2020 for routes to diagnosis data. In this release some of our group names have been revised to more concise or more meaningful names. This better aligns us with other NDRS publications. For example, the group which was previously called 'Ovary, fallopian tube and primary peritoneal carcinomas' is now called 'Ovary', and the group which was previously called 'Haematological malignancies' is now called 'Blood cancer (haematological neoplasms)'. Finally, this release includes some new columns in the incidence data. As well as publishing crude incidence rates, we are now publishing age gender standardised incidence rates along which their upper and lower confidence intervals. This will allow for better international comparison of our groups. We have also added 50 new incidence columns which break down the incidence in the whole group by different patient characteristics. These are five-year-age and gender, broad ethnicity group, and deprivation quintile. For a specific GDO group therefore (row in our output data), a user will be able to identify the incidence for that group as a whole and then the incidence in, for example, the '65-69 male' group, the '40-44 female' group, the 'Black' group, or the 'Deprivation quintile 4' group. All releases and documentation are available on the Get Data Out dashboard. Before using the data, we recommend that you read the 'Introduction', 'FAQs' and 'Known limitations' tabs. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

Projected lung cancer morality reduction and deaths avoided by smoker type, 2020–2040.

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/non-re...

Cancer mortality in Mexico increased continuously from 2012 to 2020. At the beginning of the period analyzed, 62 deaths per 100,000 people due to cancer were recorded in the North American country, compared to 71.7 deaths per 100,000 people in 2020. This figure decreased during the following two years, with 70.6 deaths per 100,000 people in 2021 and 69.6 deaths per 100,000 people in 2022. As of 2023, the mortality rate increased slightly to 70.8 deaths per 100,000 people.

Projected life-years gained, 2020–2040.

The role of religion and politics in the responses to the coronavirus pandemic raises the question of their influence on the risk of other diseases. This study focuses on age-adjusted death rates of cancer, heart disease, and infant mortality per 1000 live births before the pandemic (2018-2019) and COVID-19 in 2020-2021. Eight hypothesized predictors of health effects were analyzed by examining their correlation to age-adjusted death rates among U.S. states, percentage who pray once or more daily, Republican influence on state health policies as indicated by the percentage vote for Trump in 2016, percent of household incomes below poverty, median family income divided by a cost-of-living index, the Gini income inequality index, urban concentration of the population, physicians per capita, and public health expenditures per capita. Since prayer for divine intervention is common to otherwise diverse religious beliefs and practices, the percentage of people claiming to pray daily in each state was used to indicate potential religious influence. All of the death rates were higher in states where more people claimed to pray daily, and where Trump received a larger percentage of the vote. Except for COVID-19, the death rates were consistently lower in states with higher public health expenditures per capita. Only COVID-19 was correlated to physicians per capita, lower where there were more physicians. Corrected statistically for the other factors, income per cost of living explains no variance. Heart disease and COVID-19 death rates were higher in areas with more income inequality. All of the disease rates were in correlation with more rural populations. Correlation of daily prayer with smoking cigarettes, and neglect of public health recommendations for fruit and vegetable consumption and COVID-19 vaccination suggests that prayer may be substituted for preventive practices.

In 2023, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2023.

Snapshot img

Doxorubicin Market Size 2024-2028

The doxorubicin market size is valued to increase USD 497.4 million, at a CAGR of 6.09% from 2023 to 2028. Growing prevalence of cancer cases will drive the doxorubicin market.

Major Market Trends & Insights

North America dominated the market and accounted for a 48% growth during the forecast period.
By Formulation - Lyophilized powder segment was valued at USD 730.50 million in 2022
By Distribution Channel - Hospital pharmacy segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 72.36 million
Market Future Opportunities: USD 497.40 million
CAGR from 2023 to 2028 : 6.09%

Market Summary

The market represents a significant segment in the global cancer therapeutics industry, driven by the growing prevalence of cancer cases and the introduction of precision cancer medicine. According to the World Health Organization, there were approximately 19.3 million new cancer cases and 9.9 million deaths in 2020. Doxorubicin, an anthracycline antibiotic, is a primary chemotherapeutic agent used in the treatment of various types of cancer, including breast, lung, and heart cancer. The market's evolution is influenced by several factors, including the late diagnosis and poor survival rates of patients with cancer, creating a need for more effective and targeted therapies.
Additionally, regulatory approvals and regional market dynamics contribute to the market's ongoing development. For instance, in 2020, the FDA approved Adriamycin Liposome Injection, a doxorubicin liposome injection, for the treatment of advanced or metastatic soft tissue sarcoma. This approval marked a significant milestone in the market, expanding the application scope of doxorubicin and potentially increasing market revenue.

What will be the Size of the Doxorubicin Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Doxorubicin Market Segmented ?

The doxorubicin industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Formulation

  Lyophilized powder
  Doxorubicin injection


Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy
  Others


Geography

  North America

    US
    Canada


  Europe

    Germany
    UK


  APAC

    China


  Rest of World (ROW)

By Formulation Insights

The lyophilized powder segment is estimated to witness significant growth during the forecast period.

Request Free Sample

The Lyophilized powder segment was valued at USD 730.50 million in 2018 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 48% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Doxorubicin Market Demand is Rising in North America Request Free Sample

The market is experiencing significant growth, with North America holding the largest share in 2023. This region's dominance can be attributed to the increasing prevalence of cancer, particularly breast cancer, which is the second leading cause of cancer deaths among women in the US. According to the Centers for Disease Control and Prevention (CDC), approximately 13% of US women will develop invasive breast cancer throughout their lifetime.

This statistic underscores the substantial demand for doxorubicin, a key anticancer drug used in the treatment of various types of cancer, including breast cancer. The market's expansion is driven by the rising incidence of cancer and the drug's efficacy in cancer treatment.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

In The market, a significant focus lies in devising effective cardiotoxicity management strategies to mitigate the mechanisms of doxorubicin-induced cardiotoxicity. The therapeutic index of doxorubicin is a critical concern, driving the exploration of novel drug delivery approaches. Assessing doxorubicin treatment response and overcoming resistance mechanisms are essential aspects of clinical trials, which account for a substantial portion of research efforts. Pharmacokinetics and pharmacodynamics play a pivotal role in understanding doxorubicin's behavior within the body. Patient selection criteria for doxorubicin therapy are meticulously evaluated to minimize toxicities. Monitoring doxorubicin-related toxicities and implementing clini

Overview

New York, NY – July 28, 2025 : The global monoclonal antibodies (mAbs) for cancer market is projected to grow from US$ 78 billion in 2024 to around US$ 301.4 billion by 2034. This reflects a robust CAGR of 14.5% during the forecast period. Key drivers include rising cancer incidence, advances in biotechnology, and the increasing use of immunotherapy. Monoclonal antibodies offer a targeted approach to treatment. They attack cancer cells with precision, causing fewer side effects than traditional therapies. As demand for precision oncology rises, the market continues to show strong growth potential.

Recent GLOBOCAN data reports 20 million new cancer cases in 2022, up from 19.6 million in 2020. Cancer-related deaths stood at 9.7 million in 2022. This rising disease burden boosts demand for effective and targeted therapies. The introduction of new monoclonal antibodies and regulatory approvals is expanding treatment options. Popular types include fully human, humanized, chimeric, and murine antibodies. These drugs work through different mechanisms, such as PD-1/PD-L1 checkpoint inhibition, antibody-drug conjugates (ADCs), and naked antibodies.

Monoclonal antibodies are used in treating various cancers like breast, lung, colorectal, leukemia, and lymphoma. Their role in cancer therapy has become increasingly important. These biologics are designed to bind specific targets, helping the immune system destroy cancer cells. Because of their specificity, they often outperform chemotherapy in terms of safety and efficacy. New treatment combinations and next-generation antibodies are entering clinical use, giving healthcare providers more tools to fight cancer. This innovation supports steady market expansion across multiple oncology segments.

Geographically, North America leads the market with a 35.7% share and US$ 27.9 billion in value for 2024. The region benefits from high cancer prevalence, strong R&D investments, and supportive reimbursement structures. Europe ranks second, supported by government funding and a growing biosimilars market. Meanwhile, Asia-Pacific is the fastest-growing region. Rapid healthcare development, growing awareness, and increased access to advanced treatments fuel this growth. As these regions invest more in biotechnology, global market share continues to shift.

Key players include Roche, Merck, Amgen, Bristol-Myers Squibb, AbbVie, and AstraZeneca. These companies are developing next-generation and bispecific monoclonal antibodies. They are also exploring combination therapies to improve patient outcomes. However, the market faces challenges such as high treatment costs, tough regulatory pathways, and biosimilar competition. Despite these hurdles, opportunities remain strong. Innovations like AI-driven drug discovery and the expansion of healthcare systems in emerging markets will support future growth. As more breakthroughs emerge, the global monoclonal antibody market for cancer is set to remain a major area of focus.